Fig 1: Effect of PDI knockdown on spontaneous seizure activity in epileptic (6 week-post SE) rats.(A) Representative EEGs for control siRNA- and PDI siRNA-infused epileptic animals. (B–D) Anticonvulsive effect of PDI siRNA on spontaneous seizure activity: (B) the mean seizure frequency, (C) seizure duration and (D) behavioral seizure score (Open circles indicate each individual value. Closed circles indicate mean value. *p < 0.05 vs. control siRNA; n = 5, respectively). PDI knockdown inhibits the spontaneous seizure activity in chronic epileptic rats. (E) Co-immunoprecipitation analyses of NR1 or NR2A interaction with PDI in control siRNA- and PDI siRNA-infused epileptic animals. M, molecular weight marker. (F) The quantitative analyses of co-immunoprecipitation of PDI bound to NR1 and NR2A (*p < 0.05 vs. control siRNA; n = 7, respectively). (G) Western blot data for the amounts of -SH + -SNO on NR1 and NR2A subunits in normal (N), control siRNA- and PDI siRNA-infused epileptic animals. M, molecular weight marker. (H,I) Quantification of effects of PDI siRNA on the amount of -SH + -SNO on NR1 and NR2A subunit and PDI expression in epileptic rats (mean ± S.E.M.; *p < 0.05 vs. normal; n = 7, respectively). PDI siRNA infusion reduces the binding of PDI to NMDAR, the amount of -SH + -SNO of NMDAR subunits and PDI expression level in epileptic animals.
Fig 2: Effect of PDI neutralization on seizure activity and in vitro thiol reductase activity of PDI on NR1 subunit.(A–C) Effect of PDI neutralization on seizure susceptibility in response to PILO. PDI neutralization reduces seizure susceptibility in response to PILO. (A) Representative EEG traces and frequency-power spectral temporal maps in response to PILO. (B,C) Quantification of effect of PDI neutralization on SE induction, latency and total EEG power in response to PILO (mean ± S.E.M.; *p < 0.05 vs. control IgG; n = 10, respectively). (D,E) In vitro thiol reductase activity of PDI on recombinant NR1 protein. As compared to vehicle (Tris), PDI treatment significantly increases the amount of thiols on recombinant NR1 protein. (D) Western blot representing the amount of thiols on recombinant NR1 protein (the upper arrow). TMT antibody also detects the thiols on PDI (the lower arrow). M, molecular weight marker. (E) Quantification of effects of PDI on the amount of thiols on recombinant NR1 protein (mean ± S.E.M.; *p < 0.05 vs. vehicle; n = 7, respectively). (F) Effect of PDI siRNA on PDI activity in vivo (mean ± S.E.M.; *p < 0.05 vs. control siRNA; n = 7, respectively). PDI siRNA inhibits the insulin reduction activity, as compared to control siRNA. (G) Representative double immunofluorescent photo for colocazation of PDI with NR1 in the normal rat hippocampus. PDI is colocalized with NR1 clusters in perikarya and the primary dendrite (panel 1). In the distal dendrites (panel 2–3), PDI immunoreactive structures are observed as continuous tubular (ER-like) or punctuate (vesicle-like) shapes. Some PDI positive structures contain NR1 immunoreactivity (arrows) and attach to NR1 positive puncta (arrow heads). Panels 2 and 3 are high magnification images for rectangles in panels 1–2. Bar = 10 (panel 1), 5 (panel 2) and 2.5 (panel 2) μm.
Fig 3: The role of PDI in redox status of NMDAR.(A) Co-immunoprecipitation analyses of PDI interaction with IP3R, NR2A, NR2B, NR1 and M1R in the hippocampus. M, molecular weight marker. (B) The quantitative analyses of co-immunoprecipitation of PDI with NR1, NR2A, NR2B, M1R and IP3. PDI binds to NR1 and NR2A more than NR2B. (C) Schematics of modified biotin switch technique for the measurement of the amount of free thiols (-SH) and S-nitrosothiols (-SNO). (D) Representative western blot for the amount of -SH + -SNO in total protein extracts. M, molecular weight marker. (E–G) Effects of PDI siRNA, DTNB and bacitracin on thiols on NR1 and NR2. The amount of -SH + -SNO on NR1 and NR2A subunits are significantly reduced by PDI siRNA, DTNB and bacitracin. (E) Western blot representing the amount of -SH + -SNO on NR1 and NR2A subunit. M, molecular weight marker. (F,G) Quantification of effects of PDI siRNA, DTNB and bacitracin on the amount of -SH + -SNO on NR1 and NR2A subunit and PDI expression (mean ± S.E.M.; *p < 0.05 vs. control; n = 7, respectively).
Fig 4: Effects of PDI knockdown on ER stress induction and excitatory receptor expressions.(A) Western blot data for ER stress makers including pPERK, pIRE1α, IRE1α and ATF6 at 7 days after PDI siRNA infusion. M, molecular weight marker. (B) Western blot data for excitatory receptors including IP3R, NR2A, NR2B, NR1, M1R and CIB1 at 7 days after PDI siRNA infusion. M, molecular weight marker. (C) Quantification of effects of PDI siRNA on levels of ER stress markers and receptor expressions (n = 7, respectively). PDI knockdown does not induce ER stress and alterations in excitatory receptor expressions.
Fig 5: Changed redox status of NMDAR by PDI in epileptic rats.(A) Western blot data for the amounts of -SH + -SNO of NR1 and NR2A subunits in non-SE (N), 3 day-post SE (3D), 1 week-post SE (1W) and chronic epileptic (6 week-post SE, Epil) animals. M, molecular weight marker. (B) Quantification of the amount of -SH + -SNO on NR1 and NR2A (mean ± S.E.M.; *p < 0.05 vs. normal; n = 7, respectively). The amounts of -SH + -SNO of NR1 and NR2A are increased 3 days after SE, and subsequently recovered to normal normal level 1 week after SE. (C) Representative photos for PDI expression in the normal and epileptic hippocampus. Bar = 300 μm. (D) Co-immunoprecipitation analyses of NR1 and NR2A interaction with PDI in normal and epileptic animals. M, molecular weight marker. (E) The quantitative analyses of co-immunoprecipitation of PDI with NR1 and NR2A in normal and epileptic animals (*p < 0.05 vs. normal; n = 7, respectively). In chronic epileptic animals, the amount of -SH + -SNO of NR1 is increased, as compared to normal animals.
Supplier Page from Novus Biologicals, a Bio-Techne Brand for Recombinant Human NMDAR1 Protein